Ostrum Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $128K | Sell |
394
-12
| -3% | -$3.91K | 0.01% | 529 |
|
|
2025
Q1 | $110K | Sell |
406
-11
| -3% | -$2.97K | 0.01% | 563 |
|
|
2024
Q4 | $98.1K | Sell |
417
-3,986
| -91% | -$938K | 0.01% | 592 |
|
|
2024
Q3 | $1.21M | Sell |
4,403
-1,339
| -23% | -$368K | 0.1% | 281 |
|
|
2024
Q2 | $1.4M | Sell |
5,742
-447
| -7% | -$109K | 0.12% | 256 |
|
|
2024
Q1 | $925K | Hold |
6,189
| – | – | 0.07% | 356 |
|
|
2023
Q4 | $1.18M | Buy |
6,189
+5,734
| +1,260% | +$1.1M | 0.1% | 283 |
|
|
2023
Q3 | $80.6K | Sell |
455
-4
| -0.9% | -$708 | 0.01% | 641 |
|
|
2023
Q2 | $87.2K | Buy |
459
+1
| +0.2% | +$190 | 0.01% | 617 |
|
|
2023
Q1 | $91.7K | Buy |
+458
| New | +$91.7K | 0.01% | 603 |
|
|
2019
Q1 | – | Sell |
-4,219
| Closed | -$308K | – | 145 |
|
|
2018
Q4 | $308K | Buy |
+4,219
| New | +$308K | 0.12% | 144 |
|